EMG
EDIT icon

Ellington Management Group’s Editas Medicine EDIT Stock Holding History

Ellington Management Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,600
Closed -$304K – 711
2017
Q1 		$304K Buy
+13,600
New +$282K 0.01% 462
2016
Q4 		– Sell
-10,757
Closed -$145K – 601
2016
Q3 		$145K Buy
+10,757
New +$220K 0.04% 582

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ellington Management Group's EDIT Position: Q2 2017 in Review

Ellington Management Group sold out of Editas Medicine (EDIT) in Q2 2017, closing a stake of 13,600 shares — an estimated $304K sold.

Ellington Management Group first reported a position in EDIT in Q3 2016 and held it in 2 quarters. The position peaked at $304K in Q1 2017. 110 funds tracked by Wall St. Rank hold EDIT as of Q2 2017.

  • Ellington Management Group reported no remaining Editas Medicine position as of Q2 2017 after selling out during the quarter.
  • Ellington Management Group sold 13,600 Editas Medicine shares in Q2 2017, an estimated $304K.
  • Ellington Management Group first reported a position in Editas Medicine in Q3 2016 and held it in 2 quarters.
  • Ellington Management Group's Editas Medicine position peaked at $304K in Q1 2017.
  • 110 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2017.

Based on Ellington Management Group's 13F filing for Q2 2017, filed 14 Aug 2017.